Comparison of tolerance and nutritional outcome between a peptide and a standard enteral formula in critically ill, hypoalbuminemic patients.
Dipeptides have been reported to be more efficiently absorbed from the gastrointestinal tract than free amino acids. The objective of this study was to compare prospectively a peptide enteral formula (PEF) with a standard enteral formula (SEF) for tolerance and nutritional outcome in acutely injured, hypoalbuminemic (less than 3.0 g/dL) patients who require enteral nutrition support. The prevalence of diarrhea and elevated gastric residuals was assessed daily. Prealbumin, transferrin, colloid oncotic pressure, Prognostic Nutritional Index, and nitrogen balance were measured on days 0, 5, and 10 of enteral nutrition support. Forty-one patients received 345 days of enteral nutrition support. Prevalences of diarrhea and elevated gastric residuals were similar between groups. Prealbumin increased and the Prognostic Nutritional Index decreased significantly from baseline at day 10 in both groups. Transferrin increased in both groups, but not significantly. Colloid oncotic pressure increased significantly from baseline at days 5 and 10 in the SEF group and day 10 in the PEF group. Nitrogen balance increased significantly from baseline at days 5 and 10 in each group. The only significant difference between groups was for nitrogen balance at day 10, which was higher in the SEF group. We conclude based upon our selected measurements of tolerance and nutritional outcome PEF seems to offer no advantage over SEF in acutely injured, hypoalbuminemic patients.
Mowatt-Larssen
C A
CA
Department of Clinical Pharmacy, University of Tennessee, Memphis.
Brown
R O
RO
Wojtysiak
S L
SL
Kudsk
K A
KA
D000328:Adult; D016638:Critical Illness / Q000628:therapy; D003967:Diarrhea / Q000209:etiology; D004750:Enteral Nutrition / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009584:Nitrogen / Q000378:metabolism; D009752:Nutritional Status; D010455:Peptides / Q000008:administration & dosage* / Q000009:adverse effects; D011228:Prealbumin / Q000378:metabolism; D011312:Pressure; D011446:Prospective Studies; D012709:Serum Albumin / Q000172:deficiency*; D014168:Transferrin / Q000378:metabolism
D010455:Peptides; D011228:Prealbumin; D012709:Serum Albumin; D014168:Transferrin; D009584:Nitrogen